These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 5163724)

  • 21. [Risk of the appearance of inhibitors linked to the administration of factors VIII and IX. Review of the literature].
    Calvez T; Costagliola D
    Transfus Clin Biol; 1994; 1(6):427-35. PubMed ID: 7881588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Home treatment of haemophilia and Christmas disease: five years' experience.
    Rizza CR; Spooner RJ
    Br J Haematol; 1977 Sep; 37(1):53-66. PubMed ID: 588479
    [No Abstract]   [Full Text] [Related]  

  • 23. Detection of factor VIII and IX inhibitors after first exposure to heat-treated concentrates.
    Hasegawa DK; Edson JR
    Lancet; 1987 Feb; 1(8530):449. PubMed ID: 2880242
    [No Abstract]   [Full Text] [Related]  

  • 24. Cases of surgery in high-responder haemophilia patients.
    Goudemand J; Tagariello G; Lopaciuk F
    Haemophilia; 2004 Sep; 10 Suppl 2():46-9. PubMed ID: 15385046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of hemophiliacs with inhibitors].
    Fujimaki M
    Rinsho Ketsueki; 1985 Jul; 26(7):1059-68. PubMed ID: 3932719
    [No Abstract]   [Full Text] [Related]  

  • 26. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Characteristics of the diagnosis, clinical aspects and treatment of hemophilias with specific, circulating anticoagulants].
    Barkagan ZS; Sukhoveeva EIa; Eremin GF; Tolochko OI; Shevchenko VI
    Probl Gematol Pereliv Krovi; 1972 Apr; 17(4):35-41. PubMed ID: 4680852
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of hemophilia.
    Rodeghiero F
    Ric Clin Lab; 1985; 15(4):289-303. PubMed ID: 3914697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The management of bleeding in hemophilia.
    Abildgaard CF
    Adv Pediatr; 1969; 16():365-90. PubMed ID: 4899062
    [No Abstract]   [Full Text] [Related]  

  • 30. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
    Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
    Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of the hereditary coagulation disorders.
    Mason DY; Ingram GI
    Semin Hematol; 1971 Apr; 8(2):158-88. PubMed ID: 5313347
    [No Abstract]   [Full Text] [Related]  

  • 32. How to manage invasive procedures in children with haemophilia.
    Ljung RC; Knobe K
    Br J Haematol; 2012 Jun; 157(5):519-28. PubMed ID: 22390160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 34. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemophilia.
    Biggs R
    Proc R Soc Med; 1969 Sep; 62(9):913-4. PubMed ID: 4241884
    [No Abstract]   [Full Text] [Related]  

  • 36. Orthotopic liver transplantation in a patient with combined hemophilia A and B.
    Delorme MA; Adams PC; Grant D; Ghent CN; Walker IR; Wall WJ
    Am J Hematol; 1990 Feb; 33(2):136-8. PubMed ID: 2105634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of a cooperative programme of profilactic treatment for haemophilia A and B (author's transl)].
    Sangre (Barc); 1978; 23(5B):780-92. PubMed ID: 725718
    [No Abstract]   [Full Text] [Related]  

  • 38. A synopsis of current haemophilia care in Hong Kong.
    Au WY; Lee V; Kho B; Ling AS; Chan D; Chan EY; Chan GC; Cheung WW; Lau CW; Lee CY; Li RC; Li CK; Lin SY; Mak V; Sun L; Wong KH; Wong R; Yau J; Yuen HL
    Hong Kong Med J; 2011 Jun; 17(3):189-94. PubMed ID: 21636866
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Kaiml M; Kornhuber B
    Vox Sang; 1999; 77 Suppl 1():3-8. PubMed ID: 10529676
    [No Abstract]   [Full Text] [Related]  

  • 40. Trypsin clotting time (K-test) in hemophilia A and in hemophilia B1.
    Girolami A; Dal Bo Zanon R; Procidano M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):863-71. PubMed ID: 6176512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.